Exemplos de uso de Hepatic events em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Hepatic events.
Hepatitis and hepatic events.
The risk of hepatic events is greatest in the first 6 weeks of therapy.
In these the addition of Fuzeon did not increase the incidence of hepatic events.
Hepatic events related to elevated aminotransferases and progressive liver disease.
Data on potential symptoms of hepatic events were prospectively collected in this study.
The combination of linagliptin andmetformin when administered in combination with insulin may be associated with an increased risk of hepatic events.
The incidence of symptomatic hepatic events during the Viramune immediate-release lead-in phase was 0.5.
Severe skin reactions such as Stevens-Johnson syndrome and erythema multiforme; neuropsychiatric adverse reactions(including severe depression, death by suicide, psychosis-like behaviour, seizures);severe hepatic events; pancreatitis and lactic acidosis(sometimes fatal) have been reported.
After the lead-in period the incidence of symptomatic hepatic events was 2.4% in the Viramune immediate-release group and 1.6% in the Viramune prolonged-release group.
Hepatic events during post marketing use have mainly been reported in patients with predisposing factors, e.g a history of transaminase elevations before start of Kineret treatment.
Overall, there was a comparable incidence of symptomatic hepatic events among men and women enrolled in VERxVE.
In general, the Grade≥ 3 hepatic events were not associated with poor clinical outcome; subsequent follow-up values tended to show improvement to ranges allowing the patient to remain on study and continue to receive study treatment at the same or reduced dose.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis including hepatocarcinoma.
Hepatotoxicity and hepatic failure resulting in death werereported during postmarketing surveillance in HIV infected patients treated with antiretroviral agents and hydroxyurea; fatal hepatic events were reported most often in patients treated with stavudine, hydroxyurea and didanosine.
In the pooled analysis for DUET-1 and DUET-2, the incidence of hepatic events tended to be higher in co-infected subjects treated with INTELENCE compared to co-infected subjects in the placebo group.
Additional information on special populations Patients co-infected with hepatitis B and/ or hepatitis C virus Inthe pooled analysis for DUET-1 and DUET-2, the incidence of hepatic events tended to be higher in co-infected subjects treated with INTELENCE compared to co-infected subjects in the placebo group.
Women have a three fold higher riskthan men for symptomatic, often rash-associated, hepatic events(5.8% versus 2.2%), and patients with higher CD4 counts at initiation of VIRAMUNE therapy are at higher risk for symptomatic hepatic events with VIRAMUNE.
In study 1100.1526(TRANxITION) no Grade 3 or4 clinical hepatic events were observed in either treatment group.
Women have a three foldhigher risk than men for symptomatic, often rash-associated, hepatic events(5.8% versus 2.2%), and treatment-naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis including hepatocarcinoma.
A total of 40 cases were excluded from analysis as they contained only hepatic events or non-specific abdominal pain, without a diagnosis of pancreatitis or elevated serum lipase and/or amylase.
In a retrospective analysis of pooled clinical studies with Viramune immediate-release tablets, women had a three fold higher riskthan men for symptomatic, often rash-associated, hepatic events(5.8% versus 2.2%), and treatment- naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy were at higher risk for symptomatic hepatic events with nevirapine.
Few patients(1.1%; 0.4% serious) discontinued treatment due to a hepatic event.
Nevertheless, if a hepatic event is suspected, liver function should be evaluated and discontinuation of Zonegran should be considered.
However, the risk of any hepatic event continues past this period and monitoring should continue at frequent intervals.
When a hepatic event is suspected, further biological and etiological evaluation is required.
Patients with baseline elevation of ALT(e.g. due to liver metastases)may be predisposed to liver injury with a higher risk of a Grade 3-5 hepatic event or liver function test increase.
The best predictor of a serious hepatic event was elevated baseline liver function tests.
Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib.